| ||
| BioSante, Optimer boost drug stocks MarketWatch The drug developer said it has completed enrollment of a Phase III safety study for its drug LibiGel, a treatment for female sexual dysfunction. The study will examine whether the product might pose any cardiovascular or breast-cancer risks to users. ... See all stories on this topic » | ||
| Drug Stocks: VRML, PFE, AEGR TomRollins.com Vermillion strength being attributed to patent win for breast cancer drug. Pfizer Inc. (Public, NYSE:PFE). Last Market Price: 21.22, Change: +0.29, % Change: (1.39%). Shares trade in the range of 20.99 – 21.25 dollars. It has a market capitalization of ... See all stories on this topic » | ||
| Editorial: US advice is hard medicine to swallow Marlborough Express ... and Pharmac has managed to keep costs down, buying drugs on behalf of the district health boards. This has been done with a degree of ruthlessness, with some losers. The argument over the provision of Herceptin to breast cancer sufferers springs to ... See all stories on this topic » | ||
| Nine-year-old cancer victim ready for Relay for Life Evansville Courier & Press Jo Ann Brock, chair of Relay's survivor's committee, said Tuesday night's event puts the spotlight on local cancer survivors and gives them a chance to sign up for Friday's Relay. Brock was diagnosed with breast cancer in 2004 and has participated in ... See all stories on this topic » | ||
| Burglars Target Stores, Salons Selling Hair Extensions KPRC Houston Thieves stole $120000 in extensions just days before the owner was scheduled to host an event to help women who had or have breast cancer. Houston, Harris County, Missouri City and Pearland stores are joining a trend that has spread across the country. ... See all stories on this topic » | ||
| Kicking off in memory of hero Sharon Sunderland Echo FRIENDS and colleagues of a much-loved Wearside mum, who lost her battle with cancer, joined together to hold a charity football match in her honour. Sharon Dyer, who died in 2009 aged 40, was originally diagnosed with breast cancer in 2004, ... See all stories on this topic » | ||
| ||
| Benzinga's Top Pre-Market NASDAQ Gainers Benzinga LOGI's PEG ratio is 0.96. Biosante Pharmaceuticals Inc (NASDAQ: BPAX) jumped 3.78% to $3.02 in the pre-market session. BioSante completed of enrollment in its ongoing LibiGel Phase III cardiovascular and breast cancer safety study. See all stories on this topic » | ||
| ||
| U.S. Makes It Easier to Get Insurance With Pre-Existing Conditions U.S. News & World Report "You could be denied coverage if you were a breast cancer survivor or if you had a pre-existing health condition like diabetes or asthma. This forced people to skip care or medication and it has bankrupted way too many families and left people's health ... See all stories on this topic » | ||
| Today's 10 Most-Hated Stocks on the AMEX Wall St. Cheat Sheet About the company: Cel-Sci Corporation researches certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. Cel-Sci is also developing other products. ... See all stories on this topic » | ||
| Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the ... PipelineReview.com (press release) A Phase II/III study of CG-10639, a long-acting recombinant human albumin-human G-CSF to prevent chemotherapy-induced neutropenia, demonstrated similar outcomes to pegfilgrastim (PEGF), for both efficacy and safety measures in breast cancer patients. ... See all stories on this topic » | ||
| ||
| Drugs shortage warning Glasgow Evening Times Pharmacists describe having to ring round different companies to try to secure treatments. Medicines for preventing the return of breast cancer and vital drugs for transplant patients are among the lines affected. See all stories on this topic » | ||
| Biotech and Pharma News; BioSante Pharmaceuticals Completes Enrollment in ... Benzinga BioSante reported that the independent Data Monitoring Committee (DMC) reviewed unblinded data in over 3250 women enrolled and over 3450 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study including 22 ... See all stories on this topic » |
| ||
| Breast Cancer Topic: Drug-Induced Fractures Rare Taking ... Of these 59 women, 46 had taken bisphosphonates -- out of a total of 83311 Swedish women who took the drugs that year. That was a fracture rate of less than ... community.breastcancer.org/forum/73/topic/769676 | ||
| Breast cancer prevention drugs should be prescribed | Eslob Health Women at high risk of developing breast cancer should be given preventative drugs, according to an international panel of cancer experts. (...) health.eslob.net/Breast-cancer-prevention-drugs | ||
| Women With High Co-pays Prone To Stop Cancer Drug | World News Reuters Women taking breast cancer drugs are more likely to skip days or drop the treatment entirely if their co-pay is high,. Companies won't routinely pay ... www.vogez.com/women-with-high-co-pays-prone-to-stop-can... |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment